Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression.

Autor: Codocedo JF; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Mera-Reina C; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Lin PB; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Puntambekar SS; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Casali BT; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Jury N; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Martinez P; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Lasagna-Reeves CA; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Landreth GE; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Nov 15. Date of Electronic Publication: 2023 Nov 15.